We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microarrays Uncover Connection Between Genomic Errors and Neurologic Disorders

By Labmedica staff writers
Posted on 04 Feb 2008
Microarrays are providing the design capabilities, sensitivity, and resolution, which enable scientists to discover a mechanism of genomic errors associated with certain diseases.

Genomic copy number changes or translocations occurring during cell division are associated with a wide range of diseases especially developmental and neurologic disorders such as Alzheimer's, Parkinson's, and Potocki-Lupski Syndrome. When the DNA addition or deletion occurs in the wrong place, another genomic-based disorder such as Pelizaeus-Merzbacher disease (PMD) can occur. PMD is a progressive degenerative disorder of the central nervous system in which motor abilities and intellectual function deteriorate. This X-chromosome-linked neurodevelopment disorder affects males and can have particularly devastating consequences.

Scientists at Baylor College of Medicine (BCM; Houston, TX, USA), used their own SurePrint in situ synthesis platform together with Agilent (Santa Clara, CA, USA) microarrays to observe the unique way that DNA additions or deletions introduced in genes during cell division were associated the diseases. The mechanism for human genomic disorders in which segments of DNA are added or deleted during replication is called replication Fork Stalling and Template Switching (FoSTes).

Jennifer Lee, Ph.D., a member of the Baylor team, was studying PMD and found genomic changes that previous theory about DNA recombination did not explain. In some places, extra genetic material was found in the middle of a different duplication.

"The Agilent microarrays were essential in enabling us to elucidate this novel mechanism,” said BCM's James R. Lupski, M.D., Ph.D., professor of molecular and human genetics, and senior investigator in this project. Prof. Lupski pioneered the emerging field of copy number variation (CNV) in the early 1990s in the quest to understand genetic variation and the multiple molecular mechanisms for disease. Now, he and his colleagues have discovered that the DNA replication process can stall, and sometimes, switch to a different "template” rather than restarting in the same place. In addition to disease research, according to Dr. Lupski, the FoSTeS mechanism could also play an important role in studies investigating human evolution.

The findings were published in the January 2007 issue of the journal Cell.


Related Links:
Baylor College of Medicine
Agilent

New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Unit-Dose Packaging solution
HLX
New
Human Papillomavirus Multiplex Assay
Anyplex Ⅱ HPV28 Detection
New
Clostridium Difficile Test
VIDITEST C. Difficile Toxin A+B (Card) Rapid Test

Latest Molecular Diagnostics News

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer